The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent in combination, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2).
The present invention is related to compounds represented by the following formula, or salts or hydrates thereof
wherein,
T
1
represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents;
X represents a C
1-6
alkyl group which may have one or more substituents, or such;
Z
1
and Z
2
each independently represent a nitrogen atom or a group represented by the formula —CR
2
—;
R
1
and R
2
independently represent a hydrogen atom, a C
1-6
alkyl group which may have one or more substituents, or a C
1-6
alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent
The present invention is related to compounds represented by the following formula, or salts or hydrates thereof
wherein,
T
1
represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents;
X represents a C
1-6
alkyl group which may have one or more substituents, or such;
Z
1
and Z
2
each independently represent a nitrogen atom or a group represented by the formula —CR
2
—;
R
1
and R
2
independently represent a hydrogen atom, a C
1-6
alkyl group which may have one or more substituents, or a C
1-6
alkoxy group which may have one or more substituents, or such.
These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.
The present invention is related to compounds represented by the following formula, or salts or hydrates thereof
wherein,
T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents;
X represents a C1-6 alkyl group which may have one or more substituents, or such;
Z1 and Z2 each independently represent a nitrogen atom or a group represented by the formula -CR2-;
R1 and R2 independently represent a hydrogen atom, a C1-6 alkyl group which may have one or more substituents, or a C1-6 alkoxy group which may have one or more substituents, or such.
These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.